Review On: Uses of Taxane in Various Diseases

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting adverse effect of taxanes used to treat breast cancer, prostate cancer, cervical cancer, ovarian cancer. The taxanes are among the most active cytotoxic agents in oncology and are widely used in adjuvant and advanced treatment settings in multiple tumour types. In this review article few and the toxicity related to taxane has been shown. Such as TAPS, Arthralgia, Myalgia, Neurotoxicity, Hypersentivity, Peripheral neuropathy, Bone marrow toxicity. Paclitaxel and docetaxel are standard therapies in advanced non–small-cell lung cancer (NSCLC) and are increasingly used in earlier treatment settings. The taxanes are generally well tolerated but can be associated with severe, irreversible (and rarely life-threatening) toxicity. Premedication and special infusion sets are necessary to reduce the risk of hypersensitivity reactions. Newer taxanes are in development designed to improve the therapeutic index and ease of administration. Several agents have completed phase I/II clinical trials and are in phase III testing. Many other novel taxanes are at earlier stages of development and appear promising as single agents and in combination regimens. Safer and more effective taxanes could replace paclitaxel and docetaxel as standard treatments in NSCLC. Over the course of taxane chemotherapy and possibly improve taxane adherence in women with breast cancer. These findings, as well as whether exercise can attenuate CIPN by the end of taxane chemotherapy, should be confirmed in larger trials. The combination of a taxane, paclitaxel or docetaxel, and a platinum compound has become the systemic chemotherapy of choice for primary ovarian cancer and has demonstrated high efficacy.